Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 3,928 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Blood Pressure, High Clear all
Completed Not applicable Interventional

Renin Profiling in Selection of Initial Antihypertensive Drug

NCT00834600
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan, hydrochlorothiazide, amlodipine, hydrochlorothiazide (HCTZ) or olmesartan
Drug
Lead sponsor
The Louis & Rachel Rudin Foundation
Other
Eligibility
40 Years to 85 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
5
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 15, 2026, 10:49 PM EDT
Recruiting Not applicable Interventional

Sequential Multiple Assignment Randomized Trial to Reduce Food Insecurity

NCT07031739
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
Resource information, Community Health Worker (CHW) assistance, Medically-tailored Meals (MTM)
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 15, 2026, 10:49 PM EDT
Completed Phase 4 Interventional Results available

Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension

NCT01202175
View directory record Official record
Conditions
Pre-hypertension, Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 15, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension

NCT00863681
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Riociguat (BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 15, 2026, 10:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cause of Pigment Dispersion Syndrome

NCT00005919
View directory record Official record
Conditions
Glaucoma, Healthy, Pigment Dispersion Syndrome
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 15, 2026, 10:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Insulin Action: Role of Skeletal Muscle and Insulin-Mediated Blood Flow

NCT00018304
View directory record Official record
Conditions
Hypertension
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 15, 2026, 10:49 PM EDT
Completed Not applicable Interventional

Cholesterol, Hypertension and Glucose Education Study

NCT00815789
View directory record Official record
Conditions
Cardiovascular Disease, Diabetes
Interventions
Tailored cardiovascular risk management (Nurse-administered )
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 15, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BNP Pharmacodynamics and Effects on Metabolism in Lean and Obese Subjects

NCT01977859
View directory record Official record
Conditions
Obesity, Cardiovascular Disease, Hypertension, Diabetes
Interventions
Nesiritide, Saline
Drug
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 15, 2026, 10:49 PM EDT
Completed No phase listed Observational

Genetic and Environmental Characteristics of Primary Pulmonary Hypertension

NCT00091546
View directory record Official record
Conditions
Lung Diseases, Hypertension, Pulmonary
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
Up to 100 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Oct 15, 2026, 10:49 PM EDT
Completed Phase 3 Interventional

Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding

NCT00331188
View directory record Official record
Conditions
Esophageal Varices, Portal Hypertension, Gastric Varices, Esophageal Bleeding
Interventions
Sanvar® (vapreotide)
Drug
Lead sponsor
Debiovision
Industry
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
19
States / cities
Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2008 · Synced Oct 15, 2026, 10:49 PM EDT
Completed Phase 2 Interventional Results available

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

NCT03541603
View directory record Official record
Conditions
Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
Interventions
Levosimendan, Matching Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 15, 2026, 10:49 PM EDT
Completed Phase 3 Interventional

Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma

NCT02565173
View directory record Official record
Conditions
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD, timolol 0.5% BID, placebo BID
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 15, 2026, 10:49 PM EDT
Completed Not applicable Interventional

Sodium Watchers Program - Hypertension

NCT04076280
View directory record Official record
Conditions
Hypertension
Interventions
Sodium Watcher Program-Hypertension, Usual Care
Behavioral
Lead sponsor
Misook L. Chung
Other
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 15, 2026, 10:49 PM EDT
Completed Not applicable Interventional

Efficacy of Selective Laser Trabeculoplasty Targeting Nasal Versus Inferior 180-degree

NCT06851546
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Nasal 180° Selective Laser Trabeculoplasty (SLT), Inferior 180° Selective Laser Trabeculoplasty (SLT)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 15, 2026, 10:49 PM EDT
Completed Phase 1 Interventional

A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.

NCT00638742
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
latanoprost
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
0 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Artesia, California • Atlanta, Georgia • North Dartmouth, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 15, 2026, 10:49 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Preventing Obstetric Complications With Dietary Intervention

NCT06320054
View directory record Official record
Conditions
Gestational Diabetes, Gestational Hypertension, High Risk Pregnancy, Preeclampsia
Interventions
Maternal Health Management Program
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 15, 2026, 10:49 PM EDT
Not yet recruiting Phase 2 Interventional

Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans

NCT07602166
View directory record Official record
Conditions
Salt Sensitivity of Blood Pressure, High Blood Pressure, Inflammation, Renin-Angiotensin-Aldosterone System
Interventions
2-hydroxybenzylamine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 15, 2026, 10:49 PM EDT
Completed Phase 4 Interventional Results available

AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure

NCT01484951
View directory record Official record
Conditions
Glaucoma
Interventions
Brinzolamide 1% and timolol 0.5% fixed combination eye drops
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
20 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 15, 2026, 10:49 PM EDT
Terminated Phase 3 Interventional Results available

Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

NCT01392495
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 15, 2026, 10:49 PM EDT
Terminated Not applicable Interventional Results available

Potassium Intake-response Trial to Control Hypertension

NCT05758142
View directory record Official record
Conditions
Blood Pressure
Interventions
Potassium Chloride, Placebo
Dietary Supplement · Other
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 15, 2026, 10:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)

NCT02406586
View directory record Official record
Conditions
Hypertension, Diabetes
Interventions
Salsalate, Carvedilol, Placebo, Intralipid 20%
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 15, 2026, 10:49 PM EDT
Completed Phase 4 Interventional Results available

A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk

NCT00412113
View directory record Official record
Conditions
Dyslipidemia, Hypertension
Interventions
Amlodipine besylate, Amlodipine besylate/atorvastatin calcium single pill combination
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
51
States / cities
Birmingham, Alabama • Mesa, Arizona • Garden Grove, California + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 15, 2026, 10:49 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Antidepressant Therapy for Improved Blood Vessel Health After Preeclampsia

NCT07715669
View directory record Official record
Conditions
Preeclampsia, Endothelial Function
Interventions
Paroxetine Hydrochloride, Ascorbic acid (Vitamin C)
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 15, 2026, 10:49 PM EDT
Terminated Phase 3 Interventional

Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure

NCT01111682
View directory record Official record
Conditions
Traumatic Brain Injury, Elevated Intracranial Pressure
Interventions
Mannitol, Hypertonic Saline
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 15, 2026, 10:49 PM EDT